The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Stocks•4 May 2026•

1 min read

InflaRx Announces Positive Preclinical Safety Data for Izicopan

Key Facts

1InflaRx N.V. announced preclinical data showing low reactive metabolite formation of izicopan in human liver microsomes.

2Findings suggest a potentially lower bioactivation-related safety risk for izicopan compared to avacopan.

InflaRx N.V. has released encouraging preclinical data regarding the safety profile of its investigational oral C5aR1 inhibitor, Izicopan. The study, conducted using human liver microsomes, demonstrated low reactive metabolite formation, suggesting a favorable safety outlook. These findings indicate a potentially lower bioactivation-related safety risk for Izicopan when compared to the existing treatment Avacopan. This development is a significant milestone in mitigating early-stage clinical risks for the company's pipeline. While the data remains preclinical, it reinforces investor confidence and contributes to the stock's current upward momentum. InflaRx continues to advance the drug's development with a focus on maintaining a superior safety profile for patients.